ZNF114 is a zinc finger protein that functions as a transcriptional regulator through RNA polymerase II-specific DNA binding 1. The protein localizes to the nucleus and participates in DNA-templated transcription regulation [GO Annotations]. Mechanistically, ZNF114 operates as a KRAB-associated zinc finger protein that works with TRIM28 to suppress pro-differentiation genes in pluripotent stem cells through epigenetic modifications, including H3K9me3 deposition and DNA methylation of target gene promoters 2. This mechanism enables maintenance of pluripotency and self-renewal capacity. Clinically, ZNF114 expression patterns are associated with disease outcomes across multiple cancer types. In pancreatic ductal adenocarcinoma, ZNF114 is significantly differentially expressed in patients who develop venous thromboembolism, suggesting a role in cancer-associated hypercoagulability 3. In prostate cancer, ZNF114 functions as an exosome-related biomarker with predictive value for both cancer status and overall survival, demonstrating utility as a non-invasive liquid biopsy marker 1. Similarly, in oral carcinoma, ZNF114 is a component of both prognostic and diagnostic gene signatures, contributing to predictive nomograms for patient stratification 4. These findings suggest ZNF114 serves as a multi-cancer biomarker with implications for patient risk assessment.